Dr. Labow created and leads one of the country’s most popular Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) programs, hosted by Mount Sinai Hospital in New York. HIPEC, also called heated chemotherapy, treats individuals with peritoneal mesothelioma and other abdominal cancers, and is respected for its ability to lengthen the lives of individuals with late-stage or terminal cancer.
Speak with our patient care advocates to get paired with the best doctors
Available for ChatMesothelioma Hope has no affiliation with and is not endorsed or sponsored by Dr. Daniel Labow. Any contact information listed is for informational purposes only. You have the right to contact Dr. Daniel Labow directly.
Dr. Labow is known for his outstanding quality of care, putting patient needs first and foremost. He is a strong believer in using minimally invasive techniques wherever possible, as they tend to have faster recovery times and less discomfort for the patient.
Dr. Labow is the Chief of the Surgical Oncology division at Mount Sinai Hospital, Program Director of their Surgical Oncology Fellowship, and an Associate Professor at Mount Sinai Hospital.
Patients who are interested in being treated by Dr. Labow can reach him at:
Mount Sinai Hospital
1470 Madison Avenue, 3rd Floor
New York, NY 10029
(212) 241-2891
Dr. Labow is well respected for an entire career dedicated to patient health. His biggest accomplishments include:
Dr. Daniel Labow began his post-secondary education at the University of Pennsylvania, where he earned a bachelor’s degree in biology. He then obtained his MD at the Warren Alpert Medical School of the combined Dartmouth-Brown Medical Program, before completing his general surgery residency at the University of Chicago’s general surgery residency. Dr. Labow also completed a second residency at New York-Presbyterian Weill Cornell Medical Center and a fellowship in surgical oncology at the Memorial Sloan-Kettering Cancer Center.
Now at Mount Sinai Hospital, Dr. Labow holds a number of prestigious titles and positions including Chief of Surgical Oncology, Vice-Chair of Outpatient Services, Program Director of the Surgical Oncology Fellowship, and Director of the hospital’s HIPEC program. He is particularly dedicated to improving the educational program at Mount Sinai, and actively develops new processes to improve the patient experience.
Dr. Labow is also the New York State Chair of the Commission on Cancer, helping develop cancer policy and positively influence cancer initiatives.
As Chief of the Surgical Oncology Division at Mount Sinai Hospital, Dr. Labow focuses on a wide range of malignancies, including mesothelioma, pancreatic, esophageal, gastric, colon and rectal cancers, sarcomas, melanomas and liver conditions.
Dr. Labow is one the world’s leading experts in heated chemotherapy treatment for peritoneal mesothelioma, and utilizes minimally invasive surgical techniques whenever possible.
Dr. Labow has been an extraordinarily accomplished surgeon, dedicated much of his professional career to his work at Mount Sinai Hospital’s NCI-designated cancer center. He has run several clinic trials to further research on cancer and find the best treatments available. He has published dozens of medical articles and he uses his experience to teach upcoming surgical oncologists at the Icahn School of Medicine at Mount Sinai.
He also leads the HIPEC program at Mount Sinai, having personally championed the program in 2007, when heated chemotherapy was still a new treatment with many skeptics. To date, Dr. Labow has performed more than 220 heated chemotherapy procedures and helped prove HIPEC’s efficacy and viability as a cancer treatment. He is now one of the most experienced surgeons in the world for treating mesothelioma and other peritoneal cancers.
“[HIPEC is] quite unique in combating cancer and getting improved outcomes for patients who often only had months to live. We are getting patients that usually survive only months and are now living multiple years. That is a small step, and certainly, there is more room to grow. But it’s taking patients that didn’t have options and giving them more,” said Dr. Labow. “It is not the one silver bullet that everyone wants to find, and it doesn’t apply to everyone. But, it certainly has become an important part of treatment for many.”
Dr. Labow currently works at Mount Sinai Hospital, in both the medical school and Cancer Center. He is an associate professor at the Icahn School of Medicine and director of the surgical oncology fellowship. He is also highly involved with the hospital itself as Chief of Surgical Oncology and Vice-Chair of Outpatient Services.
Dr. Labow has a breadth of knowledge regarding numerous forms of cancers and applies his extensive research and education to a wide range of medical challenges. Much of his experience is with abdominal cancers, such as mesothelioma, although he also works with appendiceal, gastric, ovarian and colon cancers. Dr. Labow is currently overseeing two Phase III clinical trials for treating unresectable pancreatic cancer.
“I think that as we learn more and more about these diseases, how they start, identifying them on a genetic level, really profiling patients and categorizing and personalizing their care, we can really impact patients more directly.”
As founder and director of Mount Sinai Hospital’s HIPEC program, Dr. Labow has performed life-saving chemotherapy procedures. HIPEC, or heated chemotherapy, is a procedure that combines surgery with chemotherapy. After a tumor has been removed, the organs and tissues potentially affected by cancer cells are bathed in a warmed chemotherapy solution. Infected areas of the body are directly targeted by the medical solution, which is then absorbed by the body.Dr. Labow's Work Update
HIPEC is a highly effective form of chemotherapy that increases positive outcomes, minimizes side effects, and prevents undetected cancer cells from growing.
Dr. Labow holds a number of professional titles and is involved with many organizations, including:
In a review of peritoneal mesothelioma cases, Dr. Labow looked at the existing research in hopes of helping the medical community better understand, diagnose and treat this form of mesothelioma in the future. Because it is rarer than its pleural counterpart, peritoneal mesothelioma is not as extensively researched and understood.
His review highlights some of the challenges associated with the disease, including difficulty to diagnose, inaccurate staging, and the need for improved therapies. The study recognizes that cytoreductive surgery and heated chemotherapy is the most common first line of defense, but that chemotherapy is a more suitable treatment for some patients.
Dr. Labow ultimately concluded that peritoneal mesothelioma is diagnosed less frequently than pleural mesothelioma, existing treatments have improved but aren’t enough to drastically improve survival, and research into signal pathways is promising and should continue to be pursued.
Dr. Labow believes in delivering the best client care possible, including both treatment and preventative care measures. He uses minimally invasive techniques whenever possible.
Dr. Labow has been an integral part of the Mount Sinai team since 2004 and has helped shape its educational programs and subsequent philosophy. Mount Sinai Health System believes in patient-centric care, and their mission is “to provide compassionate patient care with seamless coordination and to advance medicine through unrivaled education, research, and outreach in the many diverse communities we serve.”
The institute combines leadership, outreach, education, clinical work, and research to achieve their vision, aiming to deliver the best possible results for every patient. Contact Dr. Labow at Mount Sinai Hospital today to receive the latest peritoneal mesothelioma treatment approaches.
Written by:Mesothelioma Hope TeamMesothelioma Hope was founded by a team of advocates to educate people about this aggressive form of cancer. Mesothelioma affects thousands of people each year. We help give hope to those impacted by mesothelioma.
If you or someone you love has been diagnosed with mesothelioma, there is hope. Contact us to learn more about mesothelioma and your treatment options.
Submit your information and a Patient Advocate will call you right back!
Hello, we’re sorry to barge in, but we are available to answer your questions.
Would you like to speak to a live person?
Get Your Free 2022 Mesothelioma Guide